This MedLibrary.org supplementary page on Scottish Medicines Consortium is provided directly from the open source Wikipedia as a service to our readers. Please see the note below on authorship of this content, as well as the Wikipedia usage guidelines. To search for other content from our encyclopedia supplement, please use the form below:
Related Sponsors
The Scottish Medicines Consortium (SMC) has the role of providing advice to NHS Boards and their Area Drug and Therapeutics Committees (ADTCs) about all newly licensed medicines. [1] It seeks to supply advice within 12 weeks of a new medicine being licenced to ensure that patients would could benefit can get access to the medicine as quickly as possible. The speed of the process has allowed the SMC to be compared favourably against the performance of the National Institute for Health and Clinical Excellence (NICE) which performs a similar role for the NHS in England and Wales.[2] On one occasion, NICE was accused of incompetence by the Royal National Institute for the Blind (RNIB) for delaying issuing advice for England and Wales about a drug that had already been approved for use in Scotland by the SMC. [3]
references
See also
Wikipedia content modification information:
- This page was last modified on 9 August 2008, at 00:16.
Wikipedia Authorship and Review
Wikipedia content provided here is not reviewed directly by MedLibrary.org. Wikipedia content is authored by an open community of volunteers and is not produced by or in any way affiliated with MedLibrary.org.
Wikipedia Usage Guidelines
This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article on "Scottish Medicines Consortium".
The URL for this specific entry is:
All Wikipedia text is available under the terms of the GNU Free Documentation License. (See Copyrights for details). Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.